vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $104.0M, roughly 1.7× Origin Bancorp, Inc.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs -0.7%, a 27.3% gap on every dollar of revenue. Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 3.9%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
AVNS vs OBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $104.0M |
| Net Profit | $-1.3M | $27.7M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 26.6% |
| Revenue YoY | 0.7% | — |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $180.9M | $103.4M | ||
| Q3 25 | $177.8M | $109.8M | ||
| Q2 25 | $175.0M | $83.5M | ||
| Q1 25 | $167.5M | $94.1M | ||
| Q4 24 | $179.6M | $78.3M | ||
| Q3 24 | $170.4M | $90.8M | ||
| Q2 24 | $171.7M | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | $-1.3M | $29.5M | ||
| Q3 25 | $-1.4M | $8.6M | ||
| Q2 25 | $-76.8M | $14.6M | ||
| Q1 25 | $6.6M | $22.4M | ||
| Q4 24 | $-397.3M | $14.3M | ||
| Q3 24 | $4.3M | $18.6M | ||
| Q2 24 | $1.8M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 36.2% | ||
| Q3 25 | 0.1% | 10.0% | ||
| Q2 25 | -42.6% | 22.3% | ||
| Q1 25 | 6.1% | 30.4% | ||
| Q4 24 | -233.0% | 23.0% | ||
| Q3 24 | 7.0% | 26.1% | ||
| Q2 24 | 3.7% | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | -0.7% | 28.5% | ||
| Q3 25 | -0.8% | 7.9% | ||
| Q2 25 | -43.9% | 17.5% | ||
| Q1 25 | 3.9% | 23.8% | ||
| Q4 24 | -221.2% | 18.2% | ||
| Q3 24 | 2.5% | 20.5% | ||
| Q2 24 | 1.0% | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-0.02 | $0.95 | ||
| Q3 25 | $-0.03 | $0.27 | ||
| Q2 25 | $-1.66 | $0.47 | ||
| Q1 25 | $0.14 | $0.71 | ||
| Q4 24 | $-8.64 | $0.45 | ||
| Q3 24 | $0.09 | $0.60 | ||
| Q2 24 | $0.04 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.3B |
| Total Assets | $1.1B | $10.2B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $89.8M | $424.2M | ||
| Q3 25 | $70.5M | $626.9M | ||
| Q2 25 | $90.3M | $334.1M | ||
| Q1 25 | $97.0M | $486.2M | ||
| Q4 24 | $107.7M | $470.2M | ||
| Q3 24 | $89.0M | $321.2M | ||
| Q2 24 | $92.2M | $288.1M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $778.2M | $1.2B | ||
| Q3 25 | $778.0M | $1.2B | ||
| Q2 25 | $776.3M | $1.2B | ||
| Q1 25 | $839.4M | $1.2B | ||
| Q4 24 | $828.5M | $1.1B | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.2B | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $1.1B | $9.7B | ||
| Q3 25 | $1.1B | $9.8B | ||
| Q2 25 | $1.0B | $9.7B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.2B | $9.7B | ||
| Q3 24 | $1.7B | $10.0B | ||
| Q2 24 | $1.7B | $9.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $158.9M | ||
| Q3 25 | $14.0M | $59.3M | ||
| Q2 25 | $6.8M | $20.6M | ||
| Q1 25 | $25.7M | $35.6M | ||
| Q4 24 | $57.9M | $108.5M | ||
| Q3 24 | $23.0M | $39.6M | ||
| Q2 24 | $27.8M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $151.1M | ||
| Q3 25 | $7.0M | $56.8M | ||
| Q2 25 | $-4.2M | $19.6M | ||
| Q1 25 | $19.0M | $34.8M | ||
| Q4 24 | $53.1M | $86.4M | ||
| Q3 24 | $20.0M | $32.2M | ||
| Q2 24 | $21.9M | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 146.0% | ||
| Q3 25 | 3.9% | 51.7% | ||
| Q2 25 | -2.4% | 23.5% | ||
| Q1 25 | 11.3% | 37.0% | ||
| Q4 24 | 29.6% | 110.3% | ||
| Q3 24 | 11.7% | 35.5% | ||
| Q2 24 | 12.8% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 7.6% | ||
| Q3 25 | 3.9% | 2.3% | ||
| Q2 25 | 6.3% | 1.2% | ||
| Q1 25 | 4.0% | 0.8% | ||
| Q4 24 | 2.7% | 28.1% | ||
| Q3 24 | 1.8% | 8.1% | ||
| Q2 24 | 3.4% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.38× | ||
| Q3 25 | — | 6.88× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | 3.89× | 1.59× | ||
| Q4 24 | — | 7.60× | ||
| Q3 24 | 5.35× | 2.13× | ||
| Q2 24 | 15.44× | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
